ClinicalTrials.gg

Program

HLX316

A development code.

In Fosun Pharma's pipeline, B7H3 x sialidase. Its studies are led by Fosun Pharma.

Furthest: phase 1, since Apr 8, 20261 company-led study, 1 open or runningNext primary completion: Dec 1, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Fosun Pharma11 open or runningphase 1since Apr 8, 2026Apr 8, 2026Dec 1, 2027phase 1 · NCT07541534
  • Named in Fosun Pharma’s own pipeline as HLX316 (B7H3 x sialidase), phase 1, as of Sep 21, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Apr 8, 2026First study: phase 1 study in Advanced/Metastatic Solid TumorsFirst studyNCT07541534 · 41 planned · China

Ahead

  1. Dec 1, 2027Primary completion: phase 1 study in Advanced/Metastatic Solid TumorsNCT07541534

TargetBeta

“B7H3 x sialidase”the company's pipeline, read by Claude · source

Other programs on CD276

ProgramCompanyFurthest phaseStudies
risvutatug rezetecanHansoh Pharmaceutical Groupphase 330
ifinatamab deruxtecanMerckphase 316
tambotatug pelitecanMediLink Therapeutics (Suzhou)phase 313
Anti-B7-H3/TOP1i Antibody-drug Conjugate SYS6043CSPC Pharmaceutical Groupphase 35
Anti-B7-H3 Antibody-drug Conjugate MHB088CruleMinghui Pharmaceuticalphase 34
Elfetabart DrozuntecanruleBioNTechphase 33
Anti-EGFR/Anti-B7-H3 Bispecific Antibody-drug Conjugate TJ101ruletj-biopharma-co-ltdphase 33
Lutetium Lu 177-DOTA-Anti-B7-H3 Monoclonal Antibody RV-01ruleradiopharm-theranostics-ltdphase 21
Autologous Anti-B7-H3 CAR T-cells BCB-276rulebrainchild-bio-incphase 21
Anti-B7-H3/CD28 Bispecific Antibody XmAb808ruleXencorphase 12
Anti-B7-H3/Anti-PTK7-TOP1i Bispecific Antibody-drug Conjugate IDE034ruleideaya-biosciencesphase 11
Anti-B7-H3/Anti-ROR1-Exatecan Bispecific Antibody-drug Conjugate NEOK001ruleneok-bio-incphase 11

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07541534Advanced/Metastatic Solid Tumors · China1RecruitingDec 1, 202741

How it is read

Names in the registry

  • “HLX316”, 1 entry

Codes read as this program: HLX316.

Conditions, from the studies’ own filings

    First seen by our ledger Nov 13, 2026.

    What this can’t show

    • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
    • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
    • Primary completion dates are the sponsors’ estimates and often move.
    • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.